Anthony D Keefe

Summary

Affiliation: Archemix Corp
Country: USA

Publications

  1. doi request reprint Aptamers as candidate therapeutics for cardiovascular indications
    Anthony D Keefe
    Archemix Corporation, 300 Third Street, Cambridge, MA 02142, USA
    Curr Opin Pharmacol 8:147-52. 2008
  2. doi request reprint SELEX with modified nucleotides
    Anthony D Keefe
    Archemix Corp, 300 Third Street, Cambridge, MA 02142, USA
    Curr Opin Chem Biol 12:448-56. 2008
  3. ncbi request reprint 2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics
    Paula E Burmeister
    Archemix Corporation, Cambridge, MA 02142, USA
    Oligonucleotides 16:337-51. 2006
  4. ncbi request reprint Direct in vitro selection of a 2'-O-methyl aptamer to VEGF
    Paula E Burmeister
    Archemix Corporation, 1 Hampshire Street, Cambridge, MA 02139, USA
    Chem Biol 12:25-33. 2005
  5. ncbi request reprint Building oligonucleotide therapeutics using non-natural chemistries
    Charles Wilson
    Archemix Corp, 300 Third Street, Cambridge, MA 02142, USA
    Curr Opin Chem Biol 10:607-14. 2006

Collaborators

Detail Information

Publications5

  1. doi request reprint Aptamers as candidate therapeutics for cardiovascular indications
    Anthony D Keefe
    Archemix Corporation, 300 Third Street, Cambridge, MA 02142, USA
    Curr Opin Pharmacol 8:147-52. 2008
    ....
  2. doi request reprint SELEX with modified nucleotides
    Anthony D Keefe
    Archemix Corp, 300 Third Street, Cambridge, MA 02142, USA
    Curr Opin Chem Biol 12:448-56. 2008
    ..Principally, the choice of modifications aims to increase aptamer potency by enhancing nuclease-resistance, or increasing target affinity by providing more target recognition functionality or generating more stable aptamer structures...
  3. ncbi request reprint 2'-Deoxy purine, 2'-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics
    Paula E Burmeister
    Archemix Corporation, Cambridge, MA 02142, USA
    Oligonucleotides 16:337-51. 2006
    ..We believe that dRmY aptamers have considerable potential as a new class of therapeutic aptamers...
  4. ncbi request reprint Direct in vitro selection of a 2'-O-methyl aptamer to VEGF
    Paula E Burmeister
    Archemix Corporation, 1 Hampshire Street, Cambridge, MA 02139, USA
    Chem Biol 12:25-33. 2005
    ..Notably, ARC245 is so stable that degradation cannot be detected after 96 hr in plasma at 37 degrees C or after autoclaving at 125 degrees C. We believe ARC245 has considerable potential as an antiangiogenesis therapeutic...
  5. ncbi request reprint Building oligonucleotide therapeutics using non-natural chemistries
    Charles Wilson
    Archemix Corp, 300 Third Street, Cambridge, MA 02142, USA
    Curr Opin Chem Biol 10:607-14. 2006
    ..The first fully modified aptamer (2'-O-methyl) was reported in 2005. It is expected that future candidate therapeutic oligonucleotides will have even more drug-like characteristics as a result of the inclusion of modified nucleotides...